免疫治疗阿尔茨海默病的研究进展.pdfVIP

11778 ()2013 12 7 24 Chin J Clinicians(Electronic Edition),December 15,2013,Vol.7,No.24  Alzheimer diseaseAD AD AβSPtau NFTAD AChE 1999 Schenk β1-42Aβ1-42PDAPP β AβAD 2000 AN17926%anti-Aβ BapineuzumabSolanezumab AD DNA AD tau Advance in immunotherapy for Alzheimer disease CHEN Yu-xin, JIANG Xiao-dan, XIAO Zhi-cheng. The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration of Guangdong; Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China Corresponding author: CHEN Yu-xin,Email: jiangxiao_dan@163.com; XIAO Zhi-cheng, Email: zhicheng.xiao@ Abstract Alzheimers disease (AD) is a kind of inevitable fatal degenerative disease of the central nervous system, mainly characterized by progressive memory disorders and intelligent recession in clinic. At present, the exact mechanisms leading to the AD are largely remained unknown. The principal neuropathological hallmarks of AD are considered as the extracellular beta-amyloid (Aβ), peptide deposition (senile plaques) and intracellular neurofibrillary tangles containing hyperphosphorylated tau protein. At present, the treatment of AD is mainly performed with some drugs, such as acetylcholinesterase (AChE) inhibitor, anti-inflammatory and antioxidant drugs to temporarily alleviate cognitive function in patients. Since Schenk, etc. significantly reduced the Aβ deposits in brains of PDAPP transgenic mice by using Aβ1-42 in 1999, a large number of active and passive immunity treatment of AD animal models have been reported. In 2000, the UK initiated clinical trials (AN1792), AD